June Lanoue is Vice President, Disease Area Commercial Leader, Rheumatology and Immunodermatology for the Immunology Therapeutic Area at Janssen Global Services. In this role, she is responsible for developing and executing the commercial strategy to support the discovery, development, and launch of new therapeutics within the Rheumatology and Immunodermatology disease areas. This involves leading a team of global commercial strategy and analytics professionals to evolve deep insights to inform differentiated development plans and lifecycle management approaches.
June also provides leadership to global commercial teams to establish effective partnerships with cross-functional and regional stakeholders to ensure worldwide launch readiness for new products and line extensions, and to maximize current in-market assets worldwide.
Prior to this role, June served as the Director of Marketing for DARZALEX® (daratumumab) in the U.S. Oncology organization at Janssen. There, she was responsible for leading a team to deliver strong growth, leveraging rapidly approaching line extensions for DARZALEX® for newly diagnosed multiple myeloma and launching DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj). Prior to the role, June was the National Sales Director for the Cardiovascular & Metabolism Therapeutic Area, leading a team of ~400 field force.
Prior to joining Janssen in July of 2016, June spent 16 years with Novartis where she led teams to deliver strong results across multiple challenging and complex market spaces including immunology, rare inflammatory diseases, transplant, asthma, dermatology, cardiovascular, and diabetes. Overall, she has led more than 15 launches across therapeutic areas.
June graduated from the State University at Binghamton, NY with a Bachelor of Arts in Comparative Literature.
Follow June on LinkedIn here.